POS0164 THE NEED FOR ANTI-OSTEOPOROTIC INTERVENTION IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS BASED ON THE FRACTURE RISK ASSESSMENT

Background: Rheumatoid arthritis (RA) is a chronic disabling disease that associated with bone loss. Previous studies estimated approximately one-third of the RA patients had osteoporosis (OP). However, most fragility fractures occur in not suffering from OP, can be partly explained by impaired quality bone, which measured DXA. Therefore, only measurement mineral density sufficient to determine indication for OP treatment. Another tool assessing need anti-osteoporotic therapy calculate 10-year probability major fracture using risk assessment (FRAX). Objectives: To assess women rheumatoid based on identification individuals and high according FRAX. Methods: 295 postmenopausal were included study. The average age was 63±7 years, duration 11 [4;16] period 13 [6; 20] years. 121 (41%) took glucocorticoids (cumulative dose 9025 [3650; 20720] mg prednisolone equivalent). A survey conducted identify factors history fractures. osteoporotic assessed FRAX tool. In treated at >7.5 equivalent estimates probabilities adjusted accordance recommendations [1]. Dual-energy X-ray absorptiometry (DXA) proximal femur performed moderate (probabilities between upper lower age-dependent intervention threshold) recalculated including femoral neck BMD. Results: 83 (28.1%) prior fracture: 44 (14,9%) – 1, 20 (6,8%) 2 19 (6.4%) 3 or more. Vertebral common, they accounted 62,1% all fractures, distal forearm second frequent localization (18.2%). Only (0.7%) hip fracture. 17 % [11; 28] women. 92 (31.2%) persons risk, 28 (9.5%) - low 175 (59.3%) risk. After recalculation BMD people 48 (16.3 %) became 9 (3.1%) very 118 (40.0%) Thus, 149 (50.5%) 146 (49,5%) FRAX, among last after 40 Conclusion: Our study demonstrated half indications treatment results References: [1]Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance adjustment glucocorticoids. Osteoporos Int. 2011;22(3):809-816. doi:10.1007/s00198-010-1524-7. Disclosure Interests: None declared